Evidence map›Paper›PMID 34808706›Full record

ArticleESC heart failure2022

Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis.

Blerim Mujaj, Zhen-Yu Zhang, Wen-Yi Yang, Lutgarde Thijs, Fang-Fei Wei, Peter Verhamme, Christian Delles, Javed Butler, Peter Sever, Roberto Latini and 4 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 7 countries.

Blerim MujajStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.ORCID 0000-0001-5831-0800
Zhen-Yu ZhangStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.ORCID 0000-0002-3785-7417
Wen-Yi YangStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.ORCID 0000-0003-1279-0866
Lutgarde ThijsStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.ORCID 0000-0002-8108-2356
Fang-Fei WeiStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.ORCID 0000-0002-9135-1660
Peter VerhammeCentre for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.ORCID 0000-0001-8698-2858
Christian DellesInstitute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.ORCID 0000-0003-2238-2612
Javed ButlerDepartment of Medicine, University of Mississippi Medical Centre, Jackson, MS, USA.ORCID 0000-0001-7683-4720
Peter SeverInternational Centre for Circulatory Health and National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-0421-2409
Roberto LatiniDepartment of Cardiovascular Medicine, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.ORCID 0000-0002-3729-4650
John Gf ClelandCardiology Department, Castle Hill Hospital, University of Hull and Imperial College London, London, UK.ORCID 0000-0002-1471-7016
Faiez ZannadINSERM, Centre d'Investigations Cliniques Plurithe'matique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.ORCID 0000-0001-7456-1570
Jan A StaessenResearch Institute Alliance for the Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium.ORCID 0000-0002-3026-1637
Heart Omics in Ageing Investigators
KU Leuven · BEBritish Heart Foundation · GBInserm · FRLung Institute · USMario Negri Institute for Pharmacological Research · ITResearch Institute of Therapy and Preventive Medicine · RUUniversity of Freiburg · DEUniversity of Hull · GBUniversity of Mississippi Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsRecent trials evaluating the effect of aspirin in the primary prevention of cardiovascular disease showed little or no benefit. However, the role of aspirin on the risk of incident heart failure (HF) remains elusive. This study aimed to evaluate the role of aspirin use on HF incidence in primary and secondary prevention and whether aspirin use increases the risk of incident HF in patients at risk. METHODS AND

resultsData from 30 827 patients at risk for HF enrolled in six observational studies were analysed [women 33.9%, mean age (±standard deviation) 66.8 ± 9.2 years]. Cardiovascular risk factors and aspirin use were recorded at baseline, and patients were followed up for the first incident of fatal or non-fatal HF. The association of incident HF with aspirin use was assessed using multivariable-adjusted proportional hazard regression, which accounted for study and cardiovascular risk factors. Over 5.3 years (median; 5th-95th percentile interval, 2.1-11.7 years), 1330 patients experienced HF. The fully adjusted hazard ratio (HR) associated with aspirin use was 1.26 [95% confidence interval (CI) 1.12-1.41; P ≤ 0.001]. Further, in a propensity-score-matched analysis, the HR was 1.26 (95% CI 1.10-1.44; P ≤ 0.001). In 22 690 patients (73.6%) without history of cardiovascular disease, the HR was 1.27 (95% CI 1.10-1.46; P = 0.001).

conclusionsIn patients, at risk, aspirin use was associated with incident HF, independent of other risk factors. In the absence of conclusive trial evidence, our observations suggest that aspirins should be prescribed with caution in patients at risk of HF or having HF.

Indexed as

Cardiovascular DiseasesHeart FailureAgedAspirinFemaleHumansIncidenceMaleMiddle AgedObservational Studies as TopicRisk FactorsAspirinAspirin useCardiovascular diseasesHeart failurePrimary preventionSecondary prevention

Identifiers

PMID34808706
PMCPMC8787993
OpenAlexW3210840363

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.